Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Bazedoxifene
Drug: Calcium/Vit D

First Posted Date: 2015-11-11

Last Posted Date: 2020-08-12

Lead Sponsor: Hanyang University

Target Recruit Count: 114

Registration Number: NCT02602704

Locations: 🇰🇷
Hanyang University, Seoul, Korea, Republic of

A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: ASP
Drug: SDPQ
Drug: 14DPQ on Day 42
Drug: 14DPQ

First Posted Date: 2015-10-30

Last Posted Date: 2017-02-01

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 320

Registration Number: NCT02592408

Locations: 🇸🇩
New Halfa Hospital, New Halfa, Kassalla, Sudan
🇸🇩
Gizeria Slang Hospital, Khartoum, Sudan

Systemic Vitamin D Supplementation in Dental Implants Patients

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Vit D

First Posted Date: 2015-10-21

Last Posted Date: 2015-10-22

Lead Sponsor: University Potiguar

Target Recruit Count: 135

Registration Number: NCT02582892

Locations: 🇧🇷
University Potiguar, Natal, RN, Brazil
🇧🇷
Gynelogical Center, Fortaleza, CE, Brazil
🇧🇷
Marco Botelho, Sao Paulo, Brazil

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54175446
Drug: Minocycline
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine
Drug: D Amphetamine Matching Placebo

First Posted Date: 2015-08-05

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 76

Registration Number: NCT02515955

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Formulation A
Drug: Formulation M1
Drug: Formulation B
Drug: Formulation M2
Drug: Formulation C
Drug: Formulation M3
Drug: Formulation D
Drug: Formulation N1
Drug: Formulation E
Drug: Formulation N2
Drug: Formulation F
Drug: Formulation N3

First Posted Date: 2015-04-27

Last Posted Date: 2018-05-15

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 12

Registration Number: NCT02426632

Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents

Phase 4

Completed

Conditions: Obesity

Interventions: Other: Normal control
Drug: Placebo
Drug: Vitamin D supplementation
Other: 3 months lifestyle and dietary management

First Posted Date: 2015-03-26

Last Posted Date: 2017-06-19

Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Target Recruit Count: 49

Registration Number: NCT02400151

Locations: 🇫🇷
CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France
🇫🇷
Institut Saint Pierre, Palavas-Les-Flots, France

A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment F
Drug: Treatment C

First Posted Date: 2015-03-11

Last Posted Date: 2017-09-07

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 48

Registration Number: NCT02385071

The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Not Applicable

Conditions: Maintenance Hemodialysis
Secondary Hyperparathyroidism

Interventions: Drug: active vitamin D
Procedure: microwave ablation

First Posted Date: 2015-01-06

Last Posted Date: 2016-05-24

Lead Sponsor: Wenhu Liu

Target Recruit Count: 30

Registration Number: NCT02332135

Locations: 🇨🇳
Beijing Friedship Hospital, Beijing, Beijing, China

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment B
Drug: Treatment C
Drug: Placebo
Drug: Treatment A
Drug: Treatment D
Drug: Moxifloxacin

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT02256735

Comparison of Changes in Serum 25(OH)D Concentrations Following Vitamin D Supplementation With Chewable Tablets Versus Pills

Phase 4

Completed

Conditions: Vitamin D Deficiency

Interventions: Drug: Vitamin D pill supplementation
Drug: Vitamin D chewable tablet supplementation

First Posted Date: 2014-06-09

Last Posted Date: 2018-07-30

Lead Sponsor: CHU de Quebec-Universite Laval

Target Recruit Count: 38

Registration Number: NCT02158598

Locations: 🇨🇦
CHU de Québec Research Centre, Laval University, Québec, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy